Large panels of human cancer cell lines have been profiled at the DNA, RNA and pharmacological levels to accelerate the search for cancer therapies. But two of those large data sets show only partial concordance. See Analysis p.389
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Nonlinear mixed-effects models for modeling in vitro drug response data to determine problematic cancer cell lines
Scientific Reports Open Access 08 October 2019
-
Systematic identification of non-coding pharmacogenomic landscape in cancer
Nature Communications Open Access 09 August 2018
-
Unearthing new genomic markers of drug response by improved measurement of discriminative power
BMC Medical Genomics Open Access 06 February 2018
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Haibe-Kains, B. et al. Nature 504, 389–393 (2013).
Shoemaker, R. H. et al. Prog. Clin. Biol. Res. 276, 265–286 (1988).
Weinstein, J. N. et al. Science 275, 343–349 (1997).
Barretina, J. et al. Nature 483, 603–607 (2012).
Garnett, M. J. et al. Nature 483, 570–575 (2012).
The Cancer Genome Atlas Research Network et al. Nature Genet. 45, 1113–1120 (2013).
Box, G. E. P. in Robustness in Statistics: Proceedings of a Workshop (eds Launer, R. L. & Wilkinson, G. N.) 201–236 (Academic, 1979).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Weinstein, J., Lorenzi, P. Discrepancies in drug sensitivity. Nature 504, 381–383 (2013). https://doi.org/10.1038/nature12839
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature12839
This article is cited by
-
To share is to be a scientist
Nature Methods (2023)
-
State-of-the-art strategies for targeting the DNA damage response in cancer
Nature Reviews Clinical Oncology (2019)
-
Nonlinear mixed-effects models for modeling in vitro drug response data to determine problematic cancer cell lines
Scientific Reports (2019)
-
Unearthing new genomic markers of drug response by improved measurement of discriminative power
BMC Medical Genomics (2018)
-
Systematic identification of non-coding pharmacogenomic landscape in cancer
Nature Communications (2018)
